|1.||Lorenc-Koci, Elzbieta: 5 articles (09/2009 - 11/2003)|
|2.||Horiguchi, Yoshie: 4 articles (01/2013 - 08/2005)|
|3.||Abe, Kenji: 4 articles (01/2013 - 08/2005)|
|4.||Taguchi, Kyoji: 4 articles (01/2013 - 08/2005)|
|5.||Saitoh, Toshiaki: 3 articles (01/2013 - 08/2005)|
|6.||Włodek, Lidia: 3 articles (01/2012 - 07/2005)|
|7.||Kwiecień, Inga: 3 articles (01/2012 - 07/2005)|
|8.||Katagiri, Nobuyuki: 2 articles (01/2013 - 03/2010)|
|9.||Nojima, Hiroshi: 2 articles (01/2013 - 03/2010)|
|10.||Kawase, Masami: 2 articles (12/2011 - 08/2009)|
|1.||Parkinsonian Disorders (Parkinsonism)
11/01/2003 - "Therefore, the aim of the study was to investigate the role of 1,2,3,4-tetrahydroisoquinoline (TIQ), an endogenous substance suspected of producing parkinsonism in humans, in the regulation of the activity of GABAergic striatopallidal pathway in rats. "
01/23/2004 - "Direct evidence for accumulation of 1,2,3,4-tetrahydroisoquinoline (TIQ), an endo- and exogenous substance suspected of producing Parkinsonism in humans, has not yet been shown. "
10/28/1988 - "1,2,3,4-Tetrahydroisoquinoline (TIQ) was quantitated by use of gas chromatography-mass spectrometry in brains and livers of marmosets which showed parkinsonism after daily subcutaneous injection of TIQ. "
05/20/2011 - "Previous studies have shown that certain 1,2,3,4-tetrahydroisoquinoline derivatives (TIQs) are neurotoxins inducing Parkinsonism. "
02/01/1998 - "Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism."
|2.||Parkinson Disease (Parkinson's Disease)
08/01/2005 - "In this article, we focus on the synthesis and pharmacological aspects of 1,2,3,4-tetrahydroisoquinoline derivatives in Parkinson's disease."
01/01/2002 - "It is well recognized that 1,2,3,4-tetrahydroisoquinoline (TIQ) is a substance capable of inducing in animals a syndrome, regarded as an animal model of Parkinson's disease. "
01/01/2000 - "Our results suggest that 1,2,3,4-tetrahydroisoquinoline may be one of the endogenous substances involved in the progress of Parkinson's disease."
02/15/1988 - "1,2,3,4-Tetrahydroisoquinoline (TIQ) has been reported to occur in human brain, with its content being 10-fold higher in the brain of a patient with Parkinson's disease (PD) than in that of a control subject. "
09/01/2001 - "We carried out behavioral, pathological, and biochemical studies in order to determine whether the stereo-structure of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1-MeTIQ) affects the onset of Parkinson's disease-like symptoms, which are induced by 1,2,3,4-tetrahydroisoquinoline (TIQ) in mice. "
01/01/2003 - "A study of the influence of newly synthesized acyclonucleosides and 1,2,3,4-tetrahydroisoquinoline derivatives on deoxythymidine and deoxycytidine kinase activities in human neurofibrosarcoma and ovarian cancer."
01/01/2003 - "1-(4-chlorophenyl)-6,7-dihydroxy- 1,2,3,4-tetrahydroisoquinoline (3), 1-(2,3-dichlorophenyl)-6,7-dihydroxy 1,2,3,4-tetrahydroisoquinoline (4) and 1-(3-methoxyphenyl)-6,7-dihydroxy 1,2,3,4-tetrahydroisoquinoline (5) at 0.2 mM concentration caused a mixed type inhibition of the synthesis of dTMP and dGMP by, on average, 33.2+/-4.4%, and reduced the content of dTTP and dGTP in the acid soluble fraction (52.6+/-3.7% of control) but were active only in the cytosol of neurofibrosarcoma. "
02/01/2007 - "In the present studies, we attempted to inhibit gammaGT activity in human hepatoblastoma (HepG2) cells to examine whether the administration of gammaGT inhibitors, acivicin (AC) and 1,2,3,4-tetrahydroisoquinoline (TIQ) influences cell proliferation and enhances cytostatic action of doxorubicin (DOX) and cisplatin (CP) on HepG2 cells. "
|5.||Ovarian Neoplasms (Ovarian Cancer)
|3.||Glutathione (Reduced Glutathione)
|4.||acivicin (AT 125)
|6.||Glutamic Acid (Glutamate)
|7.||Dizocilpine Maleate (Dizocilpine)
|8.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)
|10.||Nitric Oxide (Nitrogen Monoxide)